英文原著
1. Bando S, Fukuda D, Soeki T, Nishimoto S, Uematsu E, Matsuura T, Ise T, Tobiume T, Yamaguchi K, Yagi S, Iwase T, Yamada H, Wakatsuki T, Shimabukuro M, Sata M. Expression of NLRP3 in subcutaneous adipose tissue is associated with coronary atherosclerosis. Atherosclerosis 2015;242(2):407-14. pubmed2. Hara T, Fukuda D, Tanaka K, Higashikuni Y, Hirata Y, Nishimoto S, Yagi S, Yamada H, Soeki T, Wakatsuki T, Shimabukuro M, Sata M. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis 2015;242(2):639-646. pubmed
3. Kozuka C, Sunagawa S, Ueda R, Higa M, Ohshiro Y, Tanaka H, Shimizu-Okabe C, Takayama C, Matsushita M, Tsutsui M, Ishiuchi S, Nakata M, Yada T, Miyazaki JI, Oyadomari S, Shimabukuro M, Masuzaki H. A novel insulinotropic mechanism of whole grain-derived gamma-oryzanol via the suppression of local dopamine D receptor signalling in mouse islet. Br J Pharmacol 2015;172(18):4519-4534. pubmed
4. Kozuka C, Sunagawa S, Ueda R, Higa M, Tanaka H, Shimizu-Okabe C, Ishiuchi S, Takayama C, Matsushita M, Tsutsui M, Miyazaki J, Oyadomari S, Shimabukuro M, Masuzaki H. gamma-Oryzanol protects pancreatic beta-cells against endoplasmic reticulum stress in male mice. Endocrinology 2015;156(4):1242-50. pubmed
5. Niki T, Soeki T, Yamaguchi K, Taketani Y, Yagi S, Iwase T, Yamada H, Wakatsuki T, Shimabukuro M, Sata M. Elevated Concentration of Interferon-Inducible Protein of 10 kD (IP-10) Is Associated With Coronary Atherosclerosis. Int Heart J 2015;56(3):269-72. pubmed
6. Sakai A, Ohira T, Hosoya M, Ohtsuru A, Satoh H, Kawasaki Y, Suzuki H, Takahashi A, Kobashi G, Ozasa K, Yasumura S, Yamashita S, Kamiya K, Abe M, Fukushima Health Management Survey G. White blood cell, neutrophil, and lymphocyte counts in individuals in the evacuation zone designated by the government after the Fukushima Daiichi Nuclear Power Plant accident: the Fukushima Health Management Survey. J Epidemiol 2015;25(1):80-7. pubmed
7. Salim HM, Fukuda D, Higashikuni Y, Tanaka K, Hirata Y, Yagi S, Soeki T, Shimabukuro M, Sata M. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice. Vascul Pharmacol 2015. pubmed
8. Satoh H, Ohira T, Hosoya M, Sakai A, Watanabe T, Ohtsuru A, Kawasaki Y, Suzuki H, Takahashi A, Kobashi G, Ozasa K, Yasumura S, Yamashita S, Kamiya K, Abe M. Evacuation after the Fukushima Daiichi Nuclear Power Plant Accident Is a Cause of Diabetes: Results from the Fukushima Health Management Survey. J Diabetes Res 2015;2015:627390. pubmed
9. Shimabukuro M, Hasegawa Y, Higa M, Amano R, Yamada H, Mizushima S, Masuzaki H, Sata M. Subclinical Carotid Atherosclerosis Burden in the Japanese: Comparison between Okinawa and Nagano Residents. J Atheroscler Thromb 2015;22(8):854-68. pubmed
10. Shimabukuro M, Saito T, Higa T, Nakamura K, Masuzaki H, Sata M. Risk stratification of coronary artery disease in asymptomatic diabetic subjects using multi-detector computed tomography. Circ J 2015;79(11):2422-2429. pubmed
11. Soeki T, Yamaguchi K, Niki T, Uematsu E, Bando S, Matsuura T, Ise T, Kusunose K, Hotchi J, Tobiume T, Yagi S, Fukuda D, Taketani Y, Iwase T, Yamada H, Wakatsuki T, Shimabukuro M, Sata M. Plasma microRNA-100 is associated with coronary plaque vulnerability. Circ J 2015;79(2):413-8. pubmed
12. Yagi S, Aihara K, Akaike M, Fukuda D, Salim HM, Ishida M, Matsuura T, Ise T, Yamaguchi K, Iwase T, Yamada H, Soeki T, Wakatsuki T, Shimabukuro M, Matsumoto T, Sata M. Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J 2015;39(4):342-7. pubmed
13. Yagi S, Aihara K, Fukuda D, Takashima A, Bando M, Hara T, Nishimoto S, Ise T, Kusunose K, Yamaguchi K, Tobiume T, Iwase T, Yamada H, Soeki T, Wakatsuki T, Shimabukuro M, Akaike M, Sata M. Reduced ratio of eicosapentaenoic acid and docosahexaenoic acid to arachidonic acid is associated with early onset of acute coronary syndrome. Nutr J 2015;14(1):111. pubmed
14. Yagi S, Aihara K, Fukuda D, Takashima A, Hara T, Hotchi J, Ise T, Yamaguchi K, Tobiume T, Iwase T, Yamada H, Soeki T, Wakatsuki T, Shimabukuro M, Akaike M, Sata M. Effects of docosahexaenoic Acid on the endothelial function in patients with coronary artery disease. J Atheroscler Thromb 2015;22(5):447-54. pubmed
15. Yagi S, Takashima A, Mitsugi M, Wada T, Hotchi J, Aihara K, Hara T, Ishida M, Fukuda D, Ise T, Yamaguchi K, Tobiume T, Iwase T, Yamada H, Soeki T, Wakatsuki T, Shimabukuro M, Akaike M, Sata M. Effect of combination tablets containing amlodipine 10 mg and irbesartan 100 mg on blood pressure and cardiovascular risk factors in patients with hypertension. Ther Clin Risk Manag 2015;11:83-8. pubmed
和文著書
1. 島袋充生：肥満と尿酸代謝の関わり インスリン抵抗性・糖代謝異常 「ここまで明らかになった尿酸代謝ワールドと高尿酸血症の病態解明 診療と医学の最前線」 下村伊一郎・益崎裕章 編 メディカルレビュー社 大阪 102-109頁, 2015年 amazon
和文総説
1. 下村伊一郎, 島袋充生, 西村理明, 山岸昌一. メタボリックシンドローム合併2型糖尿病の治療戦略. Pharma Medica 2015;33(6):69-74.2. 島袋充生. 【最新エビデンスに学ぶ 効果の上がる肥満症食事療法の実践】 肥満症の最新トピックス 異所性脂肪. 臨床栄養 2015;127(4):550-553.
3. 島袋充生. 【新しい循環器病のバイオマーカー-臨床的意義を理解する-】 診療ツールとしてのバイオマーカーを識る 糖尿病. Heart View 2015;19(12):98-103.
4. 島袋充生. 【日本人肥満メタボ型糖尿病の実相、病態、治療】 肥満2型糖尿病の分子メカニズム 肥満メタボ型糖尿病と動脈硬化性疾患. The Lipid 2015;26(2):137-142.
5. 島袋充生. 【新しい代謝系・循環器系関連薬とRAS】 肥満症治療薬とRAS. Angiotensin Research 2015;12(3):138-143.
6. 島袋充生, 小塚智沙代, 益崎裕章. 【糖尿病と機能性食品】 玄米食と糖尿病. 機能性食品と薬理栄養 2015;9(3):135-139.
7. 益崎裕章, 小塚智沙代, 島袋充生. 【いま知っておきたい! 内科最新トピックス】(第10章)代謝・栄養 肥満を科学し,臨床に活かす. 内科 2015;116(6):1198-1202.
8. 益崎裕章, 小塚智沙代, 田仲秀明, 島袋充生. 糖尿病 基礎分野での進歩 玄米含有成分を活用した高脂肪食依存・嗜好性の制御. Annual Review糖尿病・代謝・内分泌 2015;2015:38-44.
